微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 48.3% | 9.97% | 16.92% | 78/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 41.31% | 131.06% | 43.22% | 92/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 28.85% | 2.92% | -34.01% | 115/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 43.71% | -6.76% | -0.48% | 90/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 43.92% | 2.01% | 145.66% | 87/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 17.88% | -60.33% | -36.21% | 139/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 28.03% | -50.87% | -40.21% | 116/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 46.88% | 0.45% | 8.87% | 88/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 43.06% | -9.16% | -4.45% | 89/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 45.07% | -8.31% | -21.01% | 87/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 57.05% | -8.59% | 22.25% | 59/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.67% | -31.17% | -1.54% | 88/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 47.4% | -38.16% | -3.56% | 84/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 49.15% | -40.84% | -21.25% | 82/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 62.42% | -19.75% | -7.95% | 48/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 67.81% | -14.57% | -11.53% | 43/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 76.65% | -7.12% | -7.74% | 30/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 83.07% | -0.94% | 6.81% | 18/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 77.78% | -8.65% | -2.01% | 26/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 79.38% | -5.44% | -3.82% | 27/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 82.53% | -3.33% | -1.6% | 18/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 83.87% | -1.56% | -1.5% | 18/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 85.14% | 0.67% | 1.43% | 13/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 83.94% | -2.79% | -1.67% | 16/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 85.37% | -1.3% | 0.2% | 12/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 85.2% | -1.5% | 0.74% | 10/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 84.57% | -1.12% | -2.06% | 11/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 86.35% | -1.76% | -0.16% | 10/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 86.49% | -1.51% | 0% | 7/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 86.49% | -0.71% | 1.13% | 10/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 85.53% | 0.04% | -2.7% | 8/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 87.9% | 9.84% | 0.09% | 8/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 87.82% | 16.65% | 0.81% | 5/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 87.11% | 25.01% | 1.89% | 6/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 85.49% | 32.32% | 6.84% | 8/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 80.02% | 38.77% | 6.29% | 15/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 75.29% | 33.59% | 8.04% | 12/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 69.68% | 25.07% | 7.84% | 17/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 64.61% | 14.14% | 12.05% | 19/159 | 46.62% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 57.66% | -3.93% | 2.32% | 36/159 | 48.17% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 56.36% | -6.65% | 1.15% | 23/159 | 45.83% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 55.71% | -7.7% | -1.57% | 28/159 | 45.93% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 56.61% | 2% | -5.69% | 21/159 | 43.86% | 贝达药业 | 97.01% | 行业排名> |